Jie-Lin Wang

Jie-Lin Wang

Auto-generated profile, based on publicly available information

Jie-Lin Wang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
PZPing-An Zhang
Ping-An Zhang
JWJie-Lin Wang
Jie-Lin Wang
SFShi-Yan Fu
Shi-Yan Fu
HLHua-Lian Luo
Hua-Lian Luo
NLNai-Jian Li
Nai-Jian Li
JLJing Li
Jing Li
Background: Allergic diseases, including allergic asthma (AA), allergic rhinitis (AR), atopic dermatitis (AD), and allergic conjunctivitis (AC), often coexist. However, the specific inflammatory mediators driving their shared mechanisms remain unclear. This study explored causal relationships and identified multiomic mediators among allergic diseases using Mendelian randomization (MR). Methods: Large‐scale GWAS datasets from FinnGen and UK Biobank were analyzed. Linkage disequilibrium score regression (LDSC) and MR–robust adjusted profile scoring (MR‐RAPS) assessed genetic correlations and causal links. Crucially, multivariable MR (MVMR) adjusted for classical type 2 inflammatory factors to isolate independent effects. A two‐step MR framework evaluated the mediating roles of immune cells, metabolites, gut microbiota, and serum proteins. Results: Six disease pairs (AA–AR, AA–AD, AR–AA, AR–AD, AD–AA, and AD–AR) showed robust causal relationships independent of type 2 inflammation markers. Mediation analyses identified key inflammatory mediators, including immune cell subsets (e.g., CD45 on granulocytes), plasma metabolites (e.g., pentose acid), gut microbiota (e.g., Bacteroides intestinalis ), and notably, serum proteins such as ABHD12 and SEZ6L2. Pathway analyses highlighted cytokine–cytokine receptor interactions and lipid metabolism. Conclusions: This study maps a comprehensive causal network of allergic multimorbidity. We identified novel serum proteins and metabolic mediators beyond the classical type 2 inflammation axis, offering potential therapeutic targets for disrupting the inflammatory crosstalk between allergic diseases.

1 March 2026 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PZPing-An Zhang
Ping-An Zhang
JWJie-Lin Wang
Jie-Lin Wang
RQRun-Dong Qin
Run-Dong Qin
XSXiao-Nan Song
Xiao-Nan Song
RMRen-Ke Mo
Ren-Ke Mo
JLJing Li
Jing Li
Atopic dermatitis (AD) involves complex metabolic–immune dysregulation, but the molecular links remain unclear. This study integrates a multilevel analytical framework to systematically investigate the metabolic–immune crosstalk in AD. Using linkage disequilibrium score regression and a two-step Mendelian randomization approach, we established genetic correlations and inferred causal relationships between plasma metabolites and inflammatory proteins, identifying 1-palmitoyl-2-arachidonoyl-GPC (PA-GPC) as a protective metabolite that exerts its effect primarily through downregulation of interleukin-18 receptor 1 (IL-18R1). Integration of single-cell transcriptomic data further revealed elevated IL-18R1 expression in T cells within the AD microenvironment and enabled stratification of T cells based on PA-GPC–associated metabolic activity, identifying 33 differentially expressed genes. Subsequent least absolute shrinkage and selection operator (LASSO) regression, combined with machine learning models and SHapley Additive exPlanations analysis, consistently prioritized CD9 as a key regulator. Functional validation showed that PA-GPC attenuates tumor necrosis factor-alpha (TNF-α)/interferon-gamma (IFN-γ)–induced inflammatory responses in human immortalized keratinocyte (HaCaT) cells and suppresses Th2 cytokine production in T cells. IL-18R1 knockdown reduced CD9 expression and Th2 cytokine production in T cells, whereas CD9 knockdown did not affect IL-18R1 expression, indicating that IL-18R1 acts upstream of CD9. Moreover, CD9 knockdown impaired T-cell viability, activation, and Th2 cytokine production. Collectively, these findings characterize metabolic–immune crosstalk in AD and identify a PA-GPC–IL-18R1–CD9 regulatory axis with potential therapeutic implications.